Literature DB >> 21903095

Development and validation of a standardized ELISA for the detection of soluble Fc-epsilon-RI in human serum.

Willem Lexmond1, John van der Mee, Floortje Ruiter, Barbara Platzer, Georg Stary, Elizabeth H Yen, Eleonora Dehlink, Samuel Nurko, Edda Fiebiger.   

Abstract

The aim of this study was to develop a standardized enzyme-linked immunosorbent assay (ELISA) for detection of human soluble Fc-epsilon-RI (sFcεRI), a serum isoform of the high affinity IgE receptor. A recombinant version of sFcεRI was produced in baculovirus and used as standard. ELISA plates were coated with anti-mouse IgG followed by incubation with the monoclonal capture antibody CRA1. This FcεRI-alpha-specific antibody binds to the stalk region of the protein and does not inhibit IgE-binding. After incubation with standards or serum samples, plates were incubated with chimeric IgE followed by detection with horseradish peroxidase conjugated anti-human IgE. Enzymatic activity was visualized with (3,3',5,5')-tetramethylbenzidine. Specificity was demonstrated by omission of capture or detection reagents. Units (U) of detection were established and the dynamic range of the assay was defined as 10-640 U/ml for a 1/5 serum dilution. Parameters of linearity (R(2)>0.999), matrix interference test (recovery of 70-110%), intra-assay variability (coefficient of variation (CV) <20%) and inter-assay variability (CV <20%) met acceptance criteria for immunoassay validation. Correlation analysis of serum units of sFcεRI measured with the new ELISA and serum IgE levels confirmed earlier published data describing a weak correlation of the two parameters in patients with elevated serum IgE while no correlation in patients with normal serum IgE or the total patient group was found. In summary, we established and validated a standardized ELISA for the detection of sFcεRI. This novel method now allows for comparative analysis of sFcεRI levels in health and disease.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903095      PMCID: PMC3196264          DOI: 10.1016/j.jim.2011.08.018

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  16 in total

1.  Fit-for-purpose method development and validation for successful biomarker measurement.

Authors:  Jean W Lee; Viswanath Devanarayan; Yu Chen Barrett; Russell Weiner; John Allinson; Scott Fountain; Stephen Keller; Ira Weinryb; Marie Green; Larry Duan; James A Rogers; Robert Millham; Peter J O'Brien; Jeff Sailstad; Masood Khan; Chad Ray; John A Wagner
Journal:  Pharm Res       Date:  2006-01-12       Impact factor: 4.200

2.  Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their alpha-chains.

Authors:  Toshiyuki Kubota; Kaori Mukai; Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 3.  New developments in FcepsilonRI regulation, function and inhibition.

Authors:  Stefan Kraft; Jean-Pierre Kinet
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

4.  Key elements of bioanalytical method validation for macromolecules.

Authors:  Marian Kelley; Binodh DeSilva
Journal:  AAPS J       Date:  2007-05-18       Impact factor: 4.009

Review 5.  Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.

Authors:  Jean W Lee; Michael Hall
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-18       Impact factor: 3.205

6.  The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients.

Authors:  R Klubal; B Osterhoff; B Wang; J P Kinet; D Maurer; G Stingl
Journal:  J Invest Dermatol       Date:  1997-03       Impact factor: 8.551

Review 7.  Allergy and asthma.

Authors:  Bruce S Bochner; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2005-05       Impact factor: 10.793

Review 8.  The role of the high-affinity IgE receptor, FcepsilonRI, in eosinophilic gastrointestinal diseases.

Authors:  Eleonora Dehlink; Edda Fiebiger
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

Review 9.  IgE in allergy and asthma today.

Authors:  Hannah J Gould; Brian J Sutton
Journal:  Nat Rev Immunol       Date:  2008-03       Impact factor: 53.106

10.  Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals.

Authors:  D Maurer; E Fiebiger; B Reininger; B Wolff-Winiski; M H Jouvin; O Kilgus; J P Kinet; G Stingl
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  4 in total

1.  Elevated levels of leukotriene C4 synthase mRNA distinguish a subpopulation of eosinophilic oesophagitis patients.

Authors:  W S Lexmond; M Pardo; K Rooney; J A Goettel; S B Snapper; E H Yen; E Dehlink; S Nurko; E Fiebiger
Journal:  Clin Exp Allergy       Date:  2013-08       Impact factor: 5.018

2.  Soluble FcɛRI: A biomarker for IgE-mediated diseases.

Authors:  Sherezade Moñino-Romero; Willem S Lexmond; Josef Singer; Christina Bannert; Abena S Amoah; Maria Yazdanbakhsh; Daniel A Boakye; Erika Jensen-Jarolim; Edda Fiebiger; Zsolt Szépfalusi
Journal:  Allergy       Date:  2019-03-11       Impact factor: 13.146

3.  The relationship between released soluble FceRI-alpha and its cell surface density on human basophils.

Authors:  Donald MacGlashan
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

4.  Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay.

Authors:  Anders Frische; Patrick Terrence Brooks; Mikkel Gybel-Brask; Susanne Gjørup Sækmose; Bitten Aagaard Jensen; Susan Mikkelsen; Mie Topholm Bruun; Lasse Boding; Charlotta Polacek Strandh; Charlotte Sværke Jørgensen; Karen Angeliki Krogfelt; Anders Fomsgaard; Ria Lassauniere
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.